A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma
- 1 August 2018
- journal article
- review article
- Published by Elsevier in Respiratory Medicine
- Vol. 141, 72-80
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trialThe Lancet Oncology, 2013
- Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experienceBMC Research Notes, 2012
- Phase II Study of Dasatinib in Patients with Previously Treated Malignant Mesothelioma (Cancer and Leukemia Group B 30601): A Brief ReportJournal of Thoracic Oncology, 2012
- Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma: SWOG S0509Journal of Thoracic Oncology, 2011
- Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: A mono-institutional experienceLung Cancer, 2011
- Life after First-line Chemotherapy in Malignant Pleural Mesothelioma: a North-East England ExperienceClinical Oncology, 2010
- Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural MesotheliomaJournal of Thoracic Oncology, 2009
- Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational studyJournal of Occupational Medicine and Toxicology, 2008
- Efficacy and safety of first‐ or second‐line irinotecan, cisplatin, and mitomycin in mesotheliomaCancer, 2006
- Measuring inconsistency in meta-analysesBMJ, 2003